These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 18811920)
1. Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels. Gooren LJ; Saad F; Haide A; Yassin A Andrologia; 2008 Oct; 40(5):298-302. PubMed ID: 18811920 [TBL] [Abstract][Full Text] [Related]
2. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate. Yassin AA; Saad F Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216 [TBL] [Abstract][Full Text] [Related]
3. Effects of various modes of androgen substitution therapy on erythropoiesis. Jockenhövel F; Vogel E; Reinhardt W; Reinwein D Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. Wang C; Harnett M; Dobs AS; Swerdloff RS J Androl; 2010; 31(5):457-65. PubMed ID: 20133964 [TBL] [Abstract][Full Text] [Related]
5. Transdermal testosterone therapy in the treatment of male hypogonadism. Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024 [TBL] [Abstract][Full Text] [Related]
7. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497 [TBL] [Abstract][Full Text] [Related]
8. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation. Giltay EJ; Haider A; Saad F; Gooren LJ Andrologia; 2008 Dec; 40(6):398-400. PubMed ID: 19032692 [TBL] [Abstract][Full Text] [Related]
9. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. Vermeulen A; Verdonck G J Clin Endocrinol Metab; 1992 Apr; 74(4):939-42. PubMed ID: 1548361 [TBL] [Abstract][Full Text] [Related]
10. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. Amory JK; Page ST; Bremner WJ J Androl; 2006; 27(1):72-8. PubMed ID: 16400081 [TBL] [Abstract][Full Text] [Related]
11. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. Stuenkel CA; Dudley RE; Yen SS J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483 [TBL] [Abstract][Full Text] [Related]
12. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group. Winters SJ; Atkinson L Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453 [TBL] [Abstract][Full Text] [Related]
14. Serum androgen bioactivity during 5alpha-dihydrotestosterone treatment in elderly men. Raivio T; Tapanainen JS; Kunelius P; Jänne OA J Androl; 2002; 23(6):919-21. PubMed ID: 12399539 [TBL] [Abstract][Full Text] [Related]
15. A ten-year safety study of the oral androgen testosterone undecanoate. Gooren LJ J Androl; 1994; 15(3):212-5. PubMed ID: 7928661 [TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study. Wang C; Iranmanesh A; Berman N; McDonald V; Steiner B; Ziel F; Faulkner SM; Dudley RE; Veldhuis JD; Swerdloff RS J Clin Endocrinol Metab; 1998 Aug; 83(8):2749-57. PubMed ID: 9709942 [TBL] [Abstract][Full Text] [Related]
17. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months. Haider A; Gooren LJ; Padungtod P; Saad F Andrologia; 2010 Dec; 42(6):349-55. PubMed ID: 21105885 [TBL] [Abstract][Full Text] [Related]
18. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. Yeap BB; Alfonso H; Chubb SA; Handelsman DJ; Hankey GJ; Almeida OP; Golledge J; Norman PE; Flicker L J Clin Endocrinol Metab; 2014 Jan; 99(1):E9-18. PubMed ID: 24257908 [TBL] [Abstract][Full Text] [Related]
19. Transdermal dihydrotestosterone treatment of 'andropause'. de Lignieres B Ann Med; 1993 Jun; 25(3):235-41. PubMed ID: 7687444 [TBL] [Abstract][Full Text] [Related]
20. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido). Moisey R; Swinburne J; Orme S Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]